A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

· To assess the anti-tumor activity of Aplidin® given as a 1-hour weekly IV infusion, in patients with Indolent non-Hodgkin’s Lymphoid neoplasm, relapsing or refractory to a prior therapy

Critère d'inclusion

Non-Hodgkin’s Lymphomas (NHLs) relapsing or refractory

Liens

ictrp
euctr